As the decreased levels of miRNA-181a in monocytes are associated with targeting IL-1 via binding the site of 3′-untranslated regions, the modulation of miRNA can alleviate systemic inflammation and thereupon decrease the severity of both MetS and OSA or even act as MetS development prevention (Xie et al., 2013a). Here, IL1B is linked to metabolic syndrome.